ProCE Banner Activity

An Expert’s Guide to ASCO 2018: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Experts in lung cancer, hematologic malignancies, and gastrointestinal and genitourinary cancers highlight key studies to watch out for at the upcoming Clinical Oncology meeting in Chicago. Our ASCO Conference Coverage program will feature downloadable summary slidesets and expert analyses of these and dozens of other clinically relevant studies presented at ASCO, providing the information you need to understand and apply the latest practice-changing oncology clinical trial findings.

Released: May 31, 2018

Expiration: May 30, 2019

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Anne S. Tsao

Anne S. Tsao, MD

Associate Professor
Director, 
Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has no real or apparent conflicts of interest to report.

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, Celgene, Gilead, and Genentech and funds for research support from Janssen.

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Pfizer, and Takeda and funds for research support from Amgen, Novartis, Pfizer, and Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has consulted with no personal compensation for AbbVie, Celgene, Janssen, Merck, and Takeda and has received funds for research support of clinical trials to his institution from AbbVie, Celgene, Janssen, Merck, Roche, sanofi‐aventis, KITE, and Takeda.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Lilly, Medivation, Millennium, Pfizer, Roche Laboratories, and sanofi-aventis; has received funds for research support from Agensys, AstraZeneca, Bayer, Clovis, Dendreon, Endocyte, Genentech, Innocrin, Johnson & Johnson, Lilly, MedImmune, Medivation, Merck, Millennium, Novartis, Pfizer, Progenics, Roche Laboratories, sanofi-aventis, and Sotio; has provided expert testimony for Celgene and sanofi-aventis; and has ownership interest in Bellicum and Tyme Pharmaceuticals.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Eli Lilly and Company, Exelixis, Genentech, Horizon Pharma, Inovio, Novartis, and Pfizer and funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer.

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consulting fees from AstraZeneca, Norvatis, and Takeda.

Anne S. Tsao, MD

Associate Professor
Director, 
Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Anne S. Tsao, MD, has disclosed that she has served on advisory boards for Ariad, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly, EMD Serono, Epizyme, Genentech, Merck, Novartis, Roche, Seattle Genetics, Sellas Life Sciences, and Takeda and received funds for research support from Ariad, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Epizyme, Genentech, Merck, Millennium, Polaris, and Seattle Genetics.